{"downloaded": true, "htmlmade": false, "full": {"id": "29407182", "source": "MED", "pmid": "29407182", "pmcid": "PMC6574123", "fullTextIdList": {"fullTextId": "PMC6574123"}, "doi": "10.1016/j.leukres.2018.01.021", "title": "Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).", "authorString": "Advani AS, Li H, Michaelis LC, Medeiros BC, Liedtke M, List AF, O'Dwyer K, Othus M, Erba HP, Appelbaum FR.", "authorList": {"author": [{"fullName": "Advani AS", "firstName": "Anjali S", "lastName": "Advani", "initials": "AS", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Dept. of Hematology/Oncology, Taussig Cancer Institute, Cleveland, OH, United States. Electronic address: advania@ccf.org."}}}, {"fullName": "Li H", "firstName": "Hongli", "lastName": "Li", "initials": "H", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "SWOG Statistical Center, Seattle, WA, United States."}}}, {"fullName": "Michaelis LC", "firstName": "Laura C", "lastName": "Michaelis", "initials": "LC", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Medical College of Wisconsin, Milwaukee, WI, United States."}}}, {"fullName": "Medeiros BC", "firstName": "Bruno C", "lastName": "Medeiros", "initials": "BC", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Dept. of Medicine, Division of Hematology, Stanford University, Stanford, CA, United States."}}}, {"fullName": "Liedtke M", "firstName": "Michaela", "lastName": "Liedtke", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Dept. of Medicine, Division of Hematology, Stanford University, Stanford, CA, United States."}}}, {"fullName": "List AF", "firstName": "Alan F", "lastName": "List", "initials": "AF", "authorId": {"@type": "ORCID", "#text": "0000-0002-1647-2972"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Dept. of Hematologic Malignancies, Moffit Cancer Center and Research Institute, Tampa, FL, United States."}}}, {"fullName": "O'Dwyer K", "firstName": "Kristen", "lastName": "O'Dwyer", "initials": "K", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, United States."}}}, {"fullName": "Othus M", "firstName": "Megan", "lastName": "Othus", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "SWOG Statistical Center, Seattle, WA, United States."}}}, {"fullName": "Erba HP", "firstName": "Harry P", "lastName": "Erba", "initials": "HP", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "University of Alabama and Birmingham and UAB Comprehensive Cancer Center, Birmingham, AL, United States."}}}, {"fullName": "Appelbaum FR", "firstName": "Frederick R", "lastName": "Appelbaum", "initials": "FR", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States."}}}]}, "authorIdList": {"authorId": {"@type": "ORCID", "#text": "0000-0002-1647-2972"}}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"volume": "67", "journalIssueId": "2664130", "dateOfPublication": "2018 Apr", "monthOfPublication": "4", "yearOfPublication": "2018", "printPublicationDate": "2018-04-01", "journal": {"title": "Leukemia research", "ISOAbbreviation": "Leuk Res", "medlineAbbreviation": "Leuk Res", "NLMid": "7706787", "ISSN": "0145-2126", "ESSN": "1873-5835"}}, "pubYear": "2018", "pageInfo": "17-20", "abstractText": "Inhibition of cholesterol synthesis and uptake sensitizes acute myeloid leukemia (AML) blasts to chemotherapy. A Phase 2 study of high dose pravastatin given in combination with idarubicin and cytarabine demonstrated an impressive response rate [75% complete remission (CR), CR with incomplete count recovery (CRi)]. However, this population was a favorable risk group as eligible patients had to have a CR/CRi lasting \u22653 months following their most recent chemotherapy. Therefore, the study was amended to treat patients with poor risk disease including those with CR/CRi <6\u202fmonths following their last induction regimen or with refractory disease. Here, we present results in this poor risk group. This trial included a significant number of patients with poor risk cytogenetics (43%) and poor risk molecular mutations. The response rate was 30% and approximately one-fourth of patients were able to proceed to allogeneic hematopoietic stem cell transplant (HSCT). The median overall survival for patients proceeding to allogeneic HSCT is 27.1 months. Although this trial did not meet criteria for a positive study based on the response rate (p\u202f=\u202f.062), these results are encouraging given the poor risk population and suggest that targeting the cholesterol pathway may have therapeutic benefit in AML.", "affiliation": "Dept. of Hematology/Oncology, Taussig Cancer Institute, Cleveland, OH, United States. Electronic address: advania@ccf.org.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Clinical Trial, Phase II", "Research Support, Non-U.S. Gov't", "research-article", "Multicenter Study", "Journal Article", "Research Support, N.I.H., Extramural"]}, "grantsList": {"grant": [{"grantId": "U10 CA016385", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "UG1 CA189854", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "N01 CA004919", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "U10 CA180819", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "U10 CA180834", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "U10 CA180855", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "U10 CA046282", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "U10 CA180888", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "U10 CA004919", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "UG1 CA189808", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "UG1 CA189856", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "UG1 CA189953", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "U10 CA180816", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "U10 CA011083", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "U10 CA046113", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Recurrence"}, {"majorTopic_YN": "N", "descriptorName": "Idarubicin", "meshQualifierList": {"meshQualifier": {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Pravastatin", "meshQualifierList": {"meshQualifier": {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Cholesterol", "meshQualifierList": {"meshQualifier": {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Cytarabine", "meshQualifierList": {"meshQualifier": {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Antineoplastic Combined Chemotherapy Protocols", "meshQualifierList": {"meshQualifier": {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Anticholesteremic Agents", "meshQualifierList": {"meshQualifier": {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Treatment Outcome"}, {"majorTopic_YN": "N", "descriptorName": "Combined Modality Therapy"}, {"majorTopic_YN": "N", "descriptorName": "Remission Induction"}, {"majorTopic_YN": "N", "descriptorName": "Hematopoietic Stem Cell Transplantation"}, {"majorTopic_YN": "N", "descriptorName": "Cytogenetic Analysis"}, {"majorTopic_YN": "N", "descriptorName": "Risk Factors"}, {"majorTopic_YN": "N", "descriptorName": "Survival Analysis"}, {"majorTopic_YN": "N", "descriptorName": "Cohort Studies"}, {"majorTopic_YN": "N", "descriptorName": "Mutation"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Leukemia, Myeloid, Acute", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}, {"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "TH", "qualifierName": "therapy", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Young Adult"}]}, "keywordList": {"keyword": ["Acute myeloid leukemia", "cytarabine", "pravastatin", "Refractory", "Relapsed", "Idarubicin"]}, "chemicalList": {"chemical": [{"name": "Anticholesteremic Agents", "registryNumber": "0"}, {"name": "Cholesterol", "registryNumber": "97C5T2UQ7J"}, {"name": "Pravastatin", "registryNumber": "KXO2KT9N0G"}, {"name": "Cytarabine", "registryNumber": "04079A1RDZ"}, {"name": "Idarubicin", "registryNumber": "ZRP63D75JW"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1016/j.leukres.2018.01.021"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6574123"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6574123?pdf=render"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1016/j.leukres.2018.01.021"}]}, "isOpenAccess": "N", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "N", "citedByCount": "6", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "authMan": "Y", "epmcAuthMan": "N", "nihAuthMan": "Y", "manuscriptId": "NIHMS939827", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2019-03-13", "dateOfCreation": "2018-02-07", "firstIndexDate": "2018-02-07", "fullTextReceivedDate": "2020-10-23", "dateOfRevision": "2020-02-25", "electronicPublicationDate": "2018-01-31", "firstPublicationDate": "2018-01-31"}, "abstract": "Inhibition of cholesterol synthesis and uptake sensitizes acute myeloid leukemia (AML) blasts to chemotherapy. A Phase 2 study of high dose pravastatin given in combination with idarubicin and cytarabine demonstrated an impressive response rate [75% complete remission (CR), CR with incomplete count recovery (CRi)]. However, this population was a favorable risk group as eligible patients had to have a CR/CRi lasting \u22653 months following their most recent chemotherapy. Therefore, the study was amended to treat patients with poor risk disease including those with CR/CRi <6\u202fmonths following their last induction regimen or with refractory disease. Here, we present results in this poor risk group. This trial included a significant number of patients with poor risk cytogenetics (43%) and poor risk molecular mutations. The response rate was 30% and approximately one-fourth of patients were able to proceed to allogeneic hematopoietic stem cell transplant (HSCT). The median overall survival for patients proceeding to allogeneic HSCT is 27.1 months. Although this trial did not meet criteria for a positive study based on the response rate (p\u202f=\u202f.062), these results are encouraging given the poor risk population and suggest that targeting the cholesterol pathway may have therapeutic benefit in AML.", "Keywords": ["Acute myeloid leukemia", "cytarabine", "pravastatin", "Refractory", "Relapsed", "Idarubicin"], "journaltitle": "Leukemia research", "authorinfo": ["Advani AS", "Li H", "Michaelis LC", "Medeiros BC", "Liedtke M", "List AF", "O'Dwyer K", "Othus M", "Erba HP", "Appelbaum FR"], "title": "Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML)."}